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Polyautoimmunity is one of the major clinical characteristics of autoimmune diseases (ADs). The aim of this study was to
investigate the prevalence of ADs in spondyloarthropathies (SpAs) and vice versa. This was a two-phase cross-sectional study.
First, we examined the presence of ADs in a cohort of patients with SpAs (N = 148). Second, we searched for the presence of
SpAs in a well-deﬁned group of patients with ADs (N = 1077) including rheumatoid arthritis (RA), systemic lupus erythematosus
(SLE), and Sj¨ ogren’s syndrome (SS). Among patients with SpAs, ankylosing spondylitis was observed in the majority of them
(55.6%). There were two patients presenting with SS in the SpA group (1.4%) and 5 patients with autoimmune thyroiditis (3.5%).
The global prevalence of ADs in SpAs was 4.86%. In the ADs group, there were 5 patients with SpAs (0.46%). Our results suggest
a lack of association between SpAs and ADs. Accordingly, SpAs might correspond more to autoinﬂammatory diseases rather than
to ADs.
1.Introduction
Spondyloarthropathies (SpAs) are a group of interrelated
diseases with joint inﬂammatory involvement such as arthri-
tis(axialandperipheral)andextraarticularinvolvementsuch
as uveitis, enthesitis, psoriasis, and inﬂammatory bowel dis-
ease (IBD).This group of diseases is characterized by familial
aggregation, absence of rheumatoid factor, and association
with human leukocyte antigen (HLA)-B27 [1]. Classically,
SpAs have been classiﬁed as ankylosing spondylitis (AS),
Reiter syndrome (RS), reactive arthritis (ReA), psoriatic
arthritis (PsA), IBD-associated SpA, and forms called undif-
ferentiated SpA (uSpA) that do not meet the criteria for
previous categories [2]. However, currently, there is a new
classiﬁcation for SpAs. This new classiﬁcation includes two
types of SpAs: axial and peripheral SpA depending on the
predominant spinal or peripheral involvement [3, 4]a n de x -
traarticular involvement such as anterior uveitis or IBD,
which are also considered part of the SpA group [5].
Autoimmune diseases (ADs), in turn, are a clinical syn-
drome caused by the loss of immune tolerance and charac-
terized by T- or B-cell activation leading to tissue damage
in the absence of any other evident cause [6]. Criteria for
AD deﬁnition have been described and revisited [7]. These
criteria, which include direct and indirect proof as well as
circumstantial evidence [6], are described in Table 1.H o w -
ever, in many diseases labeled as autoimmune, there are
several limitations to fulﬁll the concept of autoimmunity,
which are mainly related to the lack of direct proof (autoan-
tibodies and cell-mediated immunity). Conversely, autoin-
ﬂammation, deﬁned as self-directed tissue inﬂammation, is
characterized by activation of the innate immune system
determined by local factorsat speciﬁc disease-prone sites [8].
Since polyautoimmunity (i.e., the presence of two or more
well-deﬁned ADs in a single patient) is one of the major
clinical characteristics of ADs, our purpose was to look for
the association between SpAs and ADs. To do so, a cross-
sectionaltwo-phasestudywasundertaken.First,thepresence
of ADs in a cohort of patients with SpAs was examined.
Second, we searched for the presence of SpAs in a well-
deﬁned group of patients with ADs including rheumatoid
arthritis (RA), systemic lupus erythematosus (SLE), and
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Table 1: Classiﬁcation criteria for autoimmune diseases in humans. Comparison between ADs and autoinﬂammatory diseases.
Diseases
SLE RA SS AS PsA IBD
Direct proof
Antibody-mediated
Circulating ABs which alter the function + + +
L o c a l i z e d A B s +++
I C l o c a t e d a t l e s i o n ++++
Passive transference + +
Cells-mediated
In vitro T-cell proliferation in respond to autoantigen +
In vitro T-cell transference to immune-deﬁcient mice +
In vitro T-cell cytotoxicity against target organ cells + + +
Indirect proof
Disease reproduction by experimental immunization ++++++
Disease reproduction by idiotypes + + +
S p o n t a n e o u s a n i m a l m o d e l s ++++++
Animal models produced by immune system
deregulation ++++++
Circumstantial
evidence
Auto-ABs + + +
O t h e r A D a s s o c i a t i o n +++ ++
H L A a s s o c i a t i o n ++++++
Lymphocytic inﬁltration in target organ +++++
G o o d r e s p o n s e t o i m m u n e s u p p r e s s i o n ++++++
AS: ankylosing spondylitis, PsA: psoriatic arthritis, IBD: inﬂammatory bowel disease, SS: Sj¨ ogren’s syndrome, RA: rheumatoid arthritis, SLE: systemic lupus
erythematosus, AD: autoimmune disease, ABs: antibodies, and IC: immune complexes.
2.MaterialsandMethods
2.1. Study Population. A total population of 1,077 patients
from our RA, SLE, and SS database was reviewed. This da-
tabase consists of 671 patients with conﬁrmed RA, 239 with
conﬁrmed SLE, and 167 with conﬁrmed SS. All patients are
followed at the Center for Autoimmune Diseases Research
(CREA) in Bogota, Colombia. All patients met four or more
of the American College of Rheumatology (ACR) criteria for
classiﬁcation of RA and SLE [9, 10]. All patients with SS
satisﬁed 4 or more of the diagnostic criteria for primary SS
proposed by the European Community Study Group [11].
All of them required objective salivary gland involvement
(i.e., focus score >1).
A cohort of 148 patients with SpAs was consecutively
evaluated and their clinical records reviewed. All SpAs
patients were classiﬁed according to accepted international
criteria for each disease. AS patients met modiﬁed New York
criteria [12] and PsA patients satisﬁed CASPAR criteria [13].
For ulcerative colitis (UC) diagnosis was made on the basis
of clinical suspicion supported by appropriate macroscopic
ﬁndings on sigmoidoscopy or colonoscopy, typical histologi-
cal ﬁndings on biopsy, and negative stool examinations for
infectious agents. For Crohn’s disease (CD) the diagnosis
depended on demonstrating focal, asymmetric, and often
granulomatous inﬂammation. However, the studies selected
varied according to the presenting manifestations, physical
ﬁndings, and complications [14]. IBD-associated SpA diag-
nosis required criteria for any type of SpA plus ﬁndings of
UC or CD as was explained. For ReA, diagnosis was done
based on the European Spondylarthropathy Study Group
(ESSG) preliminary criteria for the classiﬁcation of SpAs
[15] and taking into account the fact that an antecedent of
previous infection was required. Patients that did not meet
the criteria for any SpA but satisﬁed the criteria for SpAs
were classiﬁed as uSpA. Patients were also classiﬁed on the
basis of the Assessment of SpondyloArthritis International
Society (ASAS) criteria for axial and peripheral involvement
[3, 4]. Patients with only extraarticular manifestations were
classiﬁed as extraarticular SpA [5]. Patients with previous
diagnostic of hypothyroidism were evaluated for autoim-
munethyroiditis(AT)bysearchingofbothantithyroglobulin
(anti-Tg) and antithyroperoxidase antibodies (anti-TPO).
2.2. Clinical Variables. Information on patient demograph-
ics and cumulative clinical and laboratory manifestations
over the course of the disease was obtained either by
veriﬁcation during discussion with the patient, an expert
evaluation by a rheumatologist, or by chart review and were
recorded in a standard and validated data-collection form
for that purpose. A search was done for data on patients
with any type of SpA and concomitant diagnoses of RA, SLE,
and SS. Each patient’s diagnosis was conﬁrmed by review of
clinical records using the criteria listed above (RA, SLE, SS,
and SpAs).
The institutional review board at the School of Medicine
and Health Sciences of the Universidad del Rosario approved
the study design, and all the patients signed the informed
consent form.
2.3. Laboratory Tests. HLA-B27 was determined by ﬂow
cytometry or DNA typing. Antinuclear antibodies were
determined by indirect immunoﬂuorescence on HEp-2 cells.
Rheumatoid factor was measured by turbidimetry. The
detection of the speciﬁc antibodies, such as anti citrullinatedAutoimmune Diseases 3
cyclic peptide (anti-CCP), native anti-DNA, anti-RNP, anti-
Sm, anti-Ro, anti-Tg, and anti-TPO antibodies were mea-
sured by Enzyme-Linked ImmunoSorbent Assay (ELISA)
by using commercial kits (QUANTA Lite ELISAs, INOVA
Diagnostics, Inc. San Diego, CA, USA) following the man-
ufacturer’s instructions.
2.4. Statistical Analysis. Univariate analysis was done on
SpA patients. For the normal variables, mean and standard
deviations (SD) are reported, and, for the nonnormal vari-
ables, interquartile ranges (IQR) are reported. Kolmogorov-
Smirnov or Shapiro-Wilk tests were done to evaluate nor-
mality as appropriate. Diﬀerences between variables were
analyzed by using T student, X2, Fisher’s exact test, ANOVA
test, or Kruskall-Wallis as appropriate. Groups presenting
n ≤ 5 were excluded from analysis. Bonferroni test was done
whensigniﬁcantdiﬀerenceswerefoundinANOVA.Inallthe
cases, a P value < 0.05 was considered as signiﬁcant. Data
were managed using the Statistical Package for the Social
Sciences software (SPSS v18 for Windows).
3. Results
3.1. General Characteristics of Two Groups of Study. At o t a l
of 148 patients with SpAs were included. AS was observed
in 55.6%, PsA in 21.5%, uSpA in 16.7%, IBD-associated
SpA in 4.2%, and ReA in 2.1% of the patients evaluated.
Disease was predominant in males for all subtypes, except
for uSpA, where a higher prevalence of females as compared
with males was observed, 66.7% versus 33.3%, respectively.
Table 2 summarizes the main clinical ﬁndings observed in
the patients with SpAs at any time during the course of
the disease, and Table 3 shows laboratory characteristics in
patients with SpA and hypothyroidism.
Regarding the group of ADs, age at onset was signiﬁcant
lower in SLE patients than RA and SS patients. Otherwise,
mean age of patients was higher in patients with RA than in
patients with SS and SLE. As expected, all the ADs in this
study were more frequent in women (Table 4).
3.2. ADs in Patients with SpAs. There were two patients
presenting with SS in the SpA group (1.4%), one with AS,
and other with PsA. There were no patients with RA or SLE
observed in the SpA group; however, one patient with uSpA
presented with HLA-B27, rheumatoid factor, and anti-CCP
antibodies but did not fulﬁll the classiﬁcation criteria for RA.
Hypothyroidism was present in 14 patients (9.5%). All of
them were women. Of these patients, ﬁve (3.5%) met criteria
for AT. Three were observed in the AS group, one in the
PsA group and one in the uSpA group. Global prevalence
of ADs in the SpA group was 4.86%. According to the new
classiﬁcationofSpAs,thepresenceofADswassimilarinboth
axial and peripheral SpA (Table 5).
3.3. SpAs in Patients with ADs. There was no patient with
concomitant AS in the group of patients with RA or in that
of patients with SLE (Table 6) .O n l yo n ec a s eo fA S( 0 . 5 9 % )
was found among 167 patients with SS. This patient did not
belong to the same group of SpAs. Among all patients with
ADsanalyzed,theprevalenceofASwas<1%.Withrespectto
PsA, one case was found in the RA group (0.15%) and none
in SLE or SS groups. The prevalence of PsA in all patients
analyzed was also low (<1%) just as in the case of RA. IBD
was presented in two patients (0.3%) in the RA group and
in one patient (0.41%) in SLE group. Prevalence of IBD in
the groups of ADs was extremely low (<1%). The overall
prevalence of SpAs was also low (0.46%).
3.4. Comparison between SpAs and ADs Prevalences. Preva-
lence of ADs in the general population is considered to be
3.23% [16]. No signiﬁcant diﬀerences between the preva-
lenceofADsinSpAsandtheprevalenceofADsinthegeneral
population were found in our study (P>0.05).
TheprevalenceofSpAsinthegeneralpopulationisabout
0.4% [17]. Signiﬁcant diﬀerences between the prevalence of
SpAs in ADs in our patients as compared to the prevalence of
SpAs in the general population were not found (P>0.05).
4. Discussion
The prevalence of SpAs in ADs observed in our study
(0.46%) was similar to the prevalence described in the
general population (<1%) [17–19]. For example, Haglund
et al. [18] found a prevalence of 0.45% for SpAs in southern
Sweden. In North America, the prevalence of SpAs has been
reported to be 0.4% [17]. Other studies on Caucasians have
shown that the frequency of AS ranges between 0.15% and
1.8% and for PsA between 0.02% and 0.2% [20].
Sundquist et al. [21] analyzed the concordant and dis-
cordant associations between RA, SLE, and AS as well as
the risk of siblings to develop these associations by using
standardized incidence ratios (SIRs). They observed concor-
dant association in siblings when AS was compared with AS
(SIRs = 17.14). In contrast, AS was not associated with RA
or SLE [21]. Information about the association of SpAs and
RA is scarce, and few case reports have been published [22–
24]. In 1981, one study including 184 patients with AS or
RS showed that ﬁve of them had concomitant diagnostic of
RA and two of these ﬁve patients presented also with Felty’s
syndrome [25]. In our study, no patient with coexisting
RA and AS was observed. However, one patient with uSpA
presented with anti-CCP antibodies, rheumatoid factor, and
HLA-B27but,atthetimeoftheinclusion,thepatientdidnot
meet criteria for RA.
There are reports of IBD in RA [26]a n dS L E[ 27]. The
present study reports a prevalence of 0.28% for IBD in all
ADs, 0.3% in RA patients, and 0.41% in SLE. No patient
withIBDwasobservedinSS.OnestudyonNorthAmericans
reported elevated risk for RA in patients with IBD, showing
an odds ratio (OR) of 2.7 with 95% conﬁdence intervals
(95% CI) between 2.4 to 3.0. However, the same study
indicated a higher risk for AS (OR: 7.8; 95% CI: 5.6–10.8)
than for RA [28]. Another study including 37 patients with
IBD showed only one patient with peripheral arthritis and
positive anti-CCP antibodies [29].
Concerning SLE, coexistence of AS is very rare, and this
association has been suggested to occur in patients who4 Autoimmune Diseases
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Table 3: Hypothyroidism in SpAs.
Classical classiﬁcation [2] New classiﬁcation [3, 4]
All
(n = 144)a
AS
(n = 80)
PsA
(n = 31)
uSpA
(n = 24) P value Axial
(n = 89)
Peripheral
(n = 55) P value
Hypothyroidism (%) 14/148 (9.5) 8/80 (10) 4 (12.9) 2 (8.3) NS 9 (10.1) 5 (9.1) NS
Anti-TPO positive 5/14 (35.7) 3/8 (37.5) 1/4 (25) 1/2 (50) NS 3/9 (33.33) 2/5 (40) NS
Anti-Tg positive 1/14 (7.14) 1/8 (12.5) 0 0 NS 1/9 (11.11) 0 NS
Both anti-TPO and
anti-Tg positives 1/14 (7.14) 1/8 (12.5) 0 0 NS 1/9 (11.11) 0 NS
AS:ankylosingspondylitis,PsA:psoriaticarthritis,uSpA:undiﬀerentiatedspondyloarthropatty,NS:nonsigniﬁcant,anti-TPO:anti-thyroperoxidase,andanti-
Tg: antithyroglobulin.
aNeither ReA (n = 3) nor exclusive extraarticular SpA were included.
Table 4: Age and gender of patients with ADs and SpAs.
Characteristic RA
(n = 671)
SLE
(n = 239)
SS
(n = 167)
SpAs
(n = 148) P value
Age, mean (SD) 51.8 (12.34) 37.1 (14.63) 50.5 (13.91) 43.78 (11.08) <0.001†
Age at onset, mean (SD) 38.7 (13.47) 29.03 (13.02) 44.2 (13.72) 34.77 (11.39) <0.001¶
Male (%) 18.3 18.2 5.3 56.9
Female (%) 81.7∗ 81.8∗ 94.7∗ 43.1
SS: Sj¨ ogren’s syndrome, RA: rheumatoid arthritis, SLE: systemic lupus erythematosus, SpAs: spondyloarthropathies, and SD: standard deviation.
†Signiﬁcant diﬀerences were observed between the following groups: RA versus SLE, RA versus SpAs, SLE versus SS, SLE versus SpAs, and SS versus SpAs.
¶Signiﬁcant diﬀerences were observed between the following groups: RA versus SLE, RA versus SS, RA versus SpAs, SLE versus SS, SLE versus SpAs, and SS
versus SpAs.
∗F e m a l e sw e r em o r ep r e v a l e n ti ne a c hg r o u p( P<0.001), but not in the SpAs group.
Table 5: ADs in patients with SpAs.
Classical classiﬁcation [2] New classiﬁcation [3, 4]
All
(n = 144)a
AS
(n = 80)
PsA
(n = 31)
uSpA
(n = 24)
Axial
(n = 89)
Peripheral
(n = 55) P value
SS 2 (1.39) 1 (1.3) 1 (3.22) 0 1 (1.12) 1 (1.81) NS
RA 0∗ 00 0 ∗ 00 ∗ NA
SLE 0 0 0 0 0 0 NA
AT 5 (3.47) 3 (3.75) 1 (3.22) 1 (4.16) 3 (3.37) 2 (3.63) NS
Total 7 (4.86) 4 (5) 2 (6.45) 1 (4.16) 4 (4.5) 3 (5.45) NS
AS: ankylosing spondylitis, PsA: psoriatic arthritis, uSpA: undiﬀerentiated spondyloarthropatty, SS: Sj¨ ogren’s syndrome, RA: rheumatoid arthritis,
SLE: systemic lupus erythematosus, AT: autoimmune thyroiditis, AD: autoimmune disease, SpAs: spondyloarthropathies, NA: not applicable, and NS:
nonsigniﬁcant.
aNeither ReA (n = 3) nor exclusive extraarticular SpA were included.
∗One patient presented with monoarthritis, HLA-B27, anti-CCP, and rheumatoid factor.
carry one or two susceptibility alleles for both diseases [30].
Furthermore, shared environmental factors that remain to
be identiﬁed may also contribute to triggering both diseases
[30]. The recently published cases of the coexistence of SLE
andAScorrespondedtodrug-inducedSLEorlupus-likesyn-
drome associated with anti TNF treatment in SpA patients
[31–33]. In our study, we did not observe patients with SpAs
in the SLE group and vice versa.
There are few reports about the coexistence of SS and
AS. Kobak et al. found SS in 10% of patients with AS in
Turkey [34]. Brandt et al. reported a prevalence of 7.6%
for SS in 105 patients with SpAs in Germany [35]. In our
study, the prevalence of SS was 1.4% in all the patients
with SpA. Diﬀerent results could be related to diagnostic
strategies (i.e., active search by performing autoantibodies
and minor salivary gland biopsy systematically), ethnicity,
and geography (i.e., environmental factors). We have no
additional evidence of SpAs in other series stressing the
scarce information in this regard.
Hypothyroidism (of any cause) was observed in 9.5% of
SpAs, and all were women. This prevalence is signiﬁcantly
higher than the prevalence of hypothyroidism in the general
population, which is considered to be 1%-2% [36]( P<
0.001). Although these results might indicate that SpAs
patients have an increased risk of hypothyroidism, the design
of this study was not intended to answer this question.
Therefore, further research in this topic is required. Of the 14
patients presenting with hypothyroidism, 5 were diagnosed6 Autoimmune Diseases
Table 6: Prevalence of SpAs in patients with ADs.
n (%) RA
(n = 671)
SLE
(n = 239)
SS
(n = 167)
All
(n = 1077)
AS 0 0 1 (0.59) 1 (0.092)
PsA 1 (0.15) 0 0 1 (0.092)
IBD 2 (0.3) 1 (0.41) 0 3 (0.28)
All SpAs 3 (0.44) 1 (0.41) 1 (0.59) 5 (0.46)
SLE: systemic lupus erythematosus, RA: rheumatoid arthritis, SS: Sj¨ ogren’s
syndrome, AS: ankylosing spondylitis, PsA: psoriatic arthritis, IBD: inﬂam-
matory bowel disease, and SpAs: spondyloarthropathies.
with AT. Thus, the prevalence of AT in SpAs in our study was
3.5%. According to the subtype of SpA, the prevalence of AT
inAS,PsA,anduSpAwas3.8%,3.2%,and4.2%,respectively.
One study carried out in Italian women with PsA showed a
high prevalence of AT as compared with controls. In such
study, 28% of PsA had anti-Tg and 14% anti-TPO antibodies
[37]. In our study, we observed a lower prevalence of AT in
PsA (Table 5), which could be due to diﬀerences in gender,
sample size, ethnicity, geography, and searching strategies.
A case of AS and multiple sclerosis (MS) has been
reported [38]; however, no patients with MS were observed
in our cohort of SpAs.
Concerning the clinical ﬁndings of our group of patients
with SpAs, the results diﬀer from other local studies to
some degree. Londo˜ no et al. [39] found a higher prevalence
of uSpA (35.3%) than we did and a lower prevalence of
PsA (9.4%) among their group of patients with SpAs. They
observed a familial history of SpA in 18% of patients and
did not ﬁnd patients with IBD-associated SpA in contrast
with our ﬁndings. Likewise, they observed male:female rate
of 3:1, but the study was made in a military hospital,
where male patients are more frequent. Another study done
by Marquez et al. [40] in the city of Medellin, included
71 patients and showed similar results to ours, although a
high prevalence of enthesitis (67%) was observed in their
patients. These diﬀerences could be due to the heterogeneity
oftheColombianpopulationandlimitednumberofpatients
analyzed in both studies as well as to ascertainment bias. Our
patients come predominantly from the city of Bogota where
the population admixture is higher than that in Medellin.
One genetic study performed on Colombians with AS did
notﬁndsigniﬁcantdiﬀerencesinHLA-B27subtypesbetween
patients from Bogota (mestizos) and Cartagena (mulattos).
However, clinical characteristics were not evaluated [41].
5. Conclusion
The ﬁndings presented in this study suggest a lack of asso-
ciation between SpAs and ADs. As a corollary, SpAs seem
to be diseases that are not autoimmune in the strict sense
even though they involve immunological reactions such as
the overproduction of particular cytokines. Therefore, we
consider them autoinﬂammatory diseases instead of autoim-
mune ones (Table 1)[ 8]. However, in spite of having
included a large number of patients, our data were under-
powered. Thus, to accurately investigate the association
between SpAs and ADs, further multicenter and collabora-
tive research is required, involving about 2000 cases and the
same number of controls to allow a statistical power of 80%
with a 5% of error.
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